Sign up to access all valuation multiples
AmorePacific Corp is a Korea-based company engaged in the manufacture and sale of beauty, personal care, and household products. The company operates through two main divisions: the Cosmetics Business Division, which includes premium and luxury brands such as Sulwhasoo, Hera, Laneige, IOPE, Aestura, and COSRX; and the Daily Beauty (DB) Business Division, which focuses on household and personal care brands including Ryeo, Mise-en-scene, and Happy Bath. It generates the majority of its revenue from the Cosmetics business division.
2006
4.7K+
LTM Revenue $2.9B
LTM EBITDA $429M
$4.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of November 2025, AmorePacific reported last 12-month revenue of $2.9B and EBITDA of $429M.
In the same period, AmorePacific generated $2.1B in LTM gross profit and $216M in net income.
See AmorePacific valuation multiples based on analyst estimatesIn the most recent fiscal year, AmorePacific reported revenue of $2.6B and EBITDA of $617M.
AmorePacific expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AmorePacific valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.9B | XXX | $2.6B | XXX | XXX | XXX |
| Gross Profit | $2.1B | XXX | $1.9B | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | $429M | XXX | $617M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $257M | XXX | $150M | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $216M | XXX | $404M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
AmorePacific has current market cap of KRW 7.73T (or $5.3B), and EV of KRW 7.20T (or $4.9B).
As of December 5, 2025, AmorePacific's stock price is KRW 112085 (or $76).
See AmorePacific trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.9B | $5.3B | XXX | XXX | XXX | XXX | $3.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAmorePacific's trades at 1.9x EV/Revenue multiple, and 7.9x EV/EBITDA.
See valuation multiples for AmorePacific and 15K+ public compsAs of December 5, 2025, AmorePacific has market cap of $5.3B and EV of $4.9B.
Equity research analysts estimate AmorePacific's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AmorePacific has a P/E ratio of 24.3x.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.3B | XXX | $5.3B | XXX | XXX | XXX |
| EV (current) | $4.9B | XXX | $4.9B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 11.4x | XXX | 7.9x | XXX | XXX | XXX |
| EV/EBIT | 19.0x | XXX | 32.7x | XXX | XXX | XXX |
| EV/Gross Profit | 2.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 24.3x | XXX | 13.0x | XXX | XXX | XXX |
| EV/FCF | 16.7x | XXX | 31.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAmorePacific's last 12 month revenue growth is 9%
AmorePacific's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.4M for the same period.
AmorePacific's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AmorePacific's rule of X is 37% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AmorePacific and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | 24% | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 65% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AmorePacific acquired XXX companies to date.
Last acquisition by AmorePacific was XXXXXXXX, XXXXX XXXXX XXXXXX . AmorePacific acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was AmorePacific founded? | AmorePacific was founded in 2006. |
| Where is AmorePacific headquartered? | AmorePacific is headquartered in South Korea. |
| How many employees does AmorePacific have? | As of today, AmorePacific has 4.7K+ employees. |
| Who is the CEO of AmorePacific? | AmorePacific's CEO is Mr. Kyung-Bae Seo. |
| Is AmorePacific publicy listed? | Yes, AmorePacific is a public company listed on KRX. |
| What is the stock symbol of AmorePacific? | AmorePacific trades under 090430 ticker. |
| When did AmorePacific go public? | AmorePacific went public in 2006. |
| Who are competitors of AmorePacific? | Similar companies to AmorePacific include e.g. Acme United, EZZ Life Science, Lavipharm, Sarantis Group. |
| What is the current market cap of AmorePacific? | AmorePacific's current market cap is $5.3B |
| What is the current revenue of AmorePacific? | AmorePacific's last 12 months revenue is $2.9B. |
| What is the current revenue growth of AmorePacific? | AmorePacific revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of AmorePacific? | Current revenue multiple of AmorePacific is 1.7x. |
| Is AmorePacific profitable? | Yes, AmorePacific is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AmorePacific? | AmorePacific's last 12 months EBITDA is $429M. |
| What is AmorePacific's EBITDA margin? | AmorePacific's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of AmorePacific? | Current EBITDA multiple of AmorePacific is 11.4x. |
| What is the current FCF of AmorePacific? | AmorePacific's last 12 months FCF is $293M. |
| What is AmorePacific's FCF margin? | AmorePacific's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of AmorePacific? | Current FCF multiple of AmorePacific is 16.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
